Skip to main
SNN
SNN logo

SNN Stock Forecast & Price Target

SNN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 0%
Buy 25%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

Smith & Nephew is experiencing underlying growth in key segments, with a notable increase of 5.5% in orthopedic products, driven by positive traction in the US market. The company has demonstrated strong performance in enabling technologies, particularly with a 23.9% underlying growth in Other Reconstruction, attributed to a significant rise in CORI placements. Furthermore, Smith & Nephew expects improved trading margins, anticipating a stronger performance in the second half of the year, supported by operational enhancements and a projected growth rate of 5% for 2025.

Bears say

Smith & Nephew's forecast for FY25 indicates potential revenue challenges, particularly in Q1, due to factors such as fewer selling days and ongoing inventory issues in China, which could hinder performance. The company's return on invested capital (ROIC) in the orthopedic segment remains significantly lower than that of its sports medicine and advanced wound management divisions, reflecting inefficiencies that may not be resolved in the near term. Additionally, the evolving US healthcare landscape poses risks from decreasing reimbursement rates, alongside persistent headwinds in the Chinese market related to political and regulatory uncertainties.

SNN has been analyzed by 4 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 25% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Smith & Nephew and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Smith & Nephew (SNN) Forecast

Analysts have given SNN a Hold based on their latest research and market trends.

According to 4 analysts, SNN has a Hold consensus rating as of Sep 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Smith & Nephew (SNN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.